Business
PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market
PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market\nPR Newswire\nSANDUSKY, Ohio, Feb. 4, 2021\n\n\n\nSANDUSKY, Ohio, Feb. 4, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today revealed plans to expand its nutraceutical product reach. The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\"\nIn addition to PAOG's ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).\nToday, PAOG is revealing for the first time a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications. The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.\nPAOG plans to establish a revenue stream this year from its nutraceuticals' initiative adding to its recently confirmed a $300,000 sales agreement executed by the company's cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.\nLast summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (USOTC: PURA). The acquisition was mad...